Bimatoprost Lens System Reduced Glaucoma Pressure
A drug-eluting lens system maintained medication-free status for most patients at one year in a recent clinical trial.
Updated on Oct. 11, 2026 in Biotech
Live Poll
Would you choose a surgical implant over daily eye drops to manage chronic glaucoma?
The Bimatoprost Drug Pad-IOL System achieved a 35 percent reduction in intraocular pressure in a 104-patient trial for glaucoma and ocular hypertension. The research-stage device maintains distance visual acuity while eliminating the need for daily eye drops for the majority of users.
Why it matters
This system addresses the high rate of non-compliance with daily eye drops by automating medication delivery at the time of surgery. The technology targets a long-term therapeutic effect, potentially replacing the lifelong reliance on topical medication for glaucoma patients.
The system utilizes two drug-eluting pads attached to an intraocular lens, which deliver medication continuously to the eye. At 12 months, participants showed a mean intraocular pressure decrease of 9 mm Hg, with all patients reaching 20/32 or better in best-corrected distance visual acuity.
The details
The device functions by housing two drug-eluting pads directly on the intraocular lens, which is then positioned inside the capsular bag—the transparent membrane that holds the natural lens. This placement keeps the medication source away from the drainage angle of the eye. Clinical data shows that endothelial cell loss, or the reduction of cells on the inner surface of the cornea, occurred at rates comparable to standard cataract surgery.
Timeline
October 9-12, 2026: Interim clinical trial results were presented at the AAO Annual Meeting.
12 months: The study recorded mean pressure reduction and medication-free patient rates.
The Tech Race
The Bimatoprost Drug Pad-IOL System represents a move toward combining vision correction with sustained-release ocular drug delivery. This approach competes with current research efforts aiming to minimize the surgical footprint while ensuring multi-year therapeutic outcomes.
If approved, this device would eliminate the requirement for daily glaucoma eye drops for patients undergoing cataract surgery. Potential candidates must weigh the benefits of a medication-free lifestyle against the risks inherent in the surgical implantation of a drug-eluting lens.
The takeaway
The clinical results establish a baseline for replacing daily pharmaceutical regimens with a passive, device-based delivery system. Watch for future multi-year trial results to confirm if the 12-month medication-free success rate holds over the intended 3-year treatment window.
What happens next
Researchers aim to demonstrate at least 3 years of continuous therapeutic treatment following a single surgical procedure.
Further reading
Learn more about the latest innovations in ocular therapeutics in our Biotech section.
Source note: This article includes information reported by Ajmc.
Live Poll
Would you choose a surgical implant over daily eye drops to manage chronic glaucoma?
